Aurora Cannabis (TSX:ACB) About to Get Transformed

Here’s why investors in Aurora Cannabis Inc (TSX:ACB)(NYSE:ACB) should expect significant transformative news from the marijuana company soon.

| More on:
Teamwork and team spirit

Image source: Getty Images

Marijuana producer and aggressive growth stock Aurora Cannabis (TSX:ACB)(NYSE:ACB) has been in the news lately over its recent connected actions towards strategic partnerships since engaging a professional investment manager, its latest lodging of a $750 million shelf prospectus, and the latest personnel hire, which indicate a serious commitment to business transformation.

The company had lagged behind in forming strategic partnerships with the major players in the alcohol, tobacco, or pharmaceuticals sectors and any other related industries after the rumoured Coca Cola deal did not materialize. Canopy Growth received a $5 billion investment from Constellation Brands, Cronos Group received a $2.4 billion injection from Altria Group, while Tilray and HEXO each signed on strategic partners.

Aurora is now on a serious drive to quickly address the partnership issue. The company signed on multi-billion-dollar hedge fund manager Nelson Peltz as a strategic advisor in March. The connected deal maker could be very instrumental in negotiating accretive partnerships for the company, and a new hire has been availed who will assist him.

Enter the shrewd investment banker

The company has just hired a former investment banker on a full-time basis.

On Thursday, April 4, the company appointed a former managing director of BMO Capital Markets, Mr Carey Squires, as executive vice president, Corporate Development and Strategy in a bid to support strategic initiatives.

The new position will report directly to the executive chair and will “focus on global growth and partnership strategies” and investor development.

Interestingly, the new hire had been a trusted advisor to the company on a several other strategic deals and he comes with deep global investment banking experience. His new employer may greatly benefit from his networks of strategic contacts as it goes on another aggressive growth spate anchored on global partnerships.

I am just wondering how the investment banker’s working week will be like as a full-time employee of a cannabis firm, tasked with “sourcing potential accretive opportunities in the global cannabis industry and negotiating favourable business transactions,” but the new role may generate a significant number of new strategic alliances for the firm if successfully executed.

A brilliant low-cost expansion strategy replay?

Most impressive and unique is the company’s propensity to hire and internalize the best people and teams for its aggressive growth endeavours.

During the productive facility build-out stage when every licensed producer was making frantic efforts to increase productive capacity, the company decided to acquire a global greenhouse design firm Larssen to create its ALPS subsidiary. The transaction saved a lot of cash for engineering consultancy and project management fees and was very strategically accretive, too.

As investor focus has shifted to strategic alliances and partnerships now, the company has hired and internalized the best brains for investment deal negotiation and structuring, and may save on paying hefty cash finder’s fees and consultancy fees.

The company may pay the new executive much less cash than what outside consultants will have charged and offer him more in stock-based compensation while tapping into his rich networks in the investment industry. The result may be very similar to the Larssen acquisition.

Larssen engineers were critical in Green Organic Dutchman and Denmark strategic deals, and the company is on track to becoming a producer of 570,000 kilograms of marijuana per annum.

I’m curious just how many partnerships the company targets to establish through Peltz and Squires for it to rule the global marijuana industry. This could mean a good number of them, and the deals may significantly transform Aurora into the great marijuana stock investors desire.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Brian Paradza has no position in any of the stocks mentioned.

More on Cannabis Stocks

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Are Cannabis Stocks Still a Thing in 2023?

The whole question of whether cannabis stocks are still relevant in 2023 is an interesting one. Here's my take on…

Read more »

A cannabis plant grows.
Cannabis Stocks

Why Canopy Growth Stock Fell 72% Last Year

Canopy Growth stock is a beaten-up cannabis giant that is trading at a discount compared to historical multiples. But is…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is SNDL Stock a Buy in January 2023?

SNDL is among the worst-performing cannabis stocks in the last three years. But is SNDL stock a buy right now?

Read more »

a person watches a downward arrow crash through the floor
Cannabis Stocks

Why Tilray Stock Fell Almost 60% in 2022

Tilray is a Canadian cannabis stock that is down 93% from all-time highs. Let's see if TLRY stock is a…

Read more »